BD unveils $1.2 billion investment in pre-fillable syringe manufacturing

World’s largest syringe maker gears up for increased demand across all product classes amid expected COVID-19 vaccine roll out

The announcement comes at a time when global demand for syringes is projected to soar with COVID-19 vaccination programmes expected to start taking off in earnest in 2021.

The company said the investment will fund capacity expansion, new product innovations, manufacturing technology enhancements and business continuity improvements across its existing network.

The six current manufacturing facilities for BD Pharmaceutical Systems that are lined up for the cash injection are in Columbus, Nebraska; Cuautitlán, Mexico; Fukushima, Japan; Le Pont-de-Claix, France; Swindon, UK; and Tatabánya, Hungary. 

“This new commitment will invest in additional upgrades at all of our Pharmaceutical Systems manufacturing facilities and across multiple product categories,” said Eric Borin, worldwide president of BD Pharmaceutical Systems.

He added that the move would provide BD with the needed surge capacity for increased pre-fillable syringe demand during times of pandemic response or periods of significant growth of new injectable drugs and vaccines.

BD, the world’s largest syringe manufacturer, is regarded as the pioneer of pre-fillable technology. The new manufacturing facility in Europe is expected to be operational by the end of 2023.